Navigation Links
Drug combination may be effective against deadly melanoma, pilot study shows
Date:3/6/2009

DURHAM, N.C. By targeting and disabling a protein frequently found in melanoma tumors, doctors may be able to make the cancer more vulnerable to chemotherapy, according to early results of a clinical study conducted by researchers in the Duke Comprehensive Cancer Center.

"In this pilot study, we gave patients with advanced extremity melanoma a compound that had been shown in pre-clinical studies to weaken melanoma tumors by targeting a protein expressed on the surface of the cancer cells. When chemotherapy was then given by infusion, it was much more effective compared to chemotherapy given alone," said Douglas Tyler, M.D., a surgeon at Duke and the Durham Veterans Affairs Medical Center, and senior investigator on this study. "Not only was the treatment well tolerated but a surprising number of this small group of patients had their tumors completely disappear."

The researchers discussed their findings in an oral presentation on March 6, 2009 at the Society of Surgical Oncology annual meeting, and results of the study have been accepted for publication in the journal Cancer. The study was funded by Adherex Technologies, the company developing the compound that was tested in combination with chemotherapy, the United States Department of Veterans Affairs, the Duke Institute for Genome Sciences & Policy, and the Duke Comprehensive Cancer Center.

Data from 16 patients treated at Duke and the University of Texas MD Anderson Cancer Center were examined for this study. Half of them experienced a complete response or an obliteration of cancer as a result of treatment, Tyler said. The compound called ADH-1 was delivered intravenously and the chemotherapy given under surgical conditions, through the artery and vein in the affected limbs.

Melanoma often affects people on their extremities, with a common scenario being a mole that appears on the foot and then spreads up the leg. Up to ten percent of patients with extremity melanoma develop multiple recurrences in the extremity that cannot be treated with surgery alone.

"These early results are very exciting because metastatic melanoma is one of the most deadly cancers and one which is typically very unresponsive to therapy," said Georgia Beasley, M.D., a surgical resident at Duke and lead author on this study. "The next step will be to continue testing the efficacy of this treatment in more patients, here and at other centers."

A larger phase II trial involving 46 patients with advanced extremity melanoma, using the same combination of drugs, was designed to try and better define the response rate in this population, Tyler said. This trial has recently completed recruiting patients and data will be forthcoming, he said.

The incidence of malignant melanoma is increasing at a rate faster than any other cancer, with 60,000 new cases expected to be diagnosed this year in the United States. Melanoma that has spread beyond the primary site is rarely curable, and treatment options are limited.


'/>"/>

Contact: Lauren Shaftel Williams
lauren.shaftel@duke.edu
919-684-4966
Duke University Medical Center
Source:Eurekalert

Related medicine news :

1. Promising drug combination may help those with ocular melanoma that has spread
2. Combination therapy reverses effects of portal hypertension in rats
3. Combination vaccines okay for infants, study shows
4. Antidepressants and painkillers - a dangerous combination
5. Intra-arterial combination chemotherapy induces long-term survival for hepatocellular carcinoma
6. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
7. Drug combination might offer hope for patients deadly brain tumors
8. EpiCept to Present Preclinical Studies of EPC2407 in Combination With Anti-Angiogenic and Chemotherpeutic Agents at the AACR-NCI-EORTC International Conference
9. Combination targets: some drugs may work best when they work together
10. MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma
11. Quality Control: Nissan Quest to Feature micronAir(R) Combination Cabin Air Filters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... 23, 2017 , ... DMG Productions is proud to announce ... scheduled to broadcast Saturday, January 28, 2017 at 5:00pmEST. , This segment will ... address the limitations of fatigue monitoring technologies within the mining industry. Today SmartCap ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... organization in North America for the scientific development, healthcare training and clinical application ... Session, and its 2017 AAT Member Certification Qualification Courses for Technicians, respectively. , ...
(Date:1/23/2017)... ... January 23, 2017 , ... "ProRandom is a set of camera tools that allow video editors ... Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. , ... text with video footage. ProRandom works by using a virtual camera to create the ...
(Date:1/23/2017)... ... January 23, 2017 , ... “Crossing the Bar”: a moving and eloquent ... life. “Crossing the Bar” is the creation of published author, Charlotte Hotte, a North ... who credits the inspiration of the book to her sister, Denise, wishes to acknowledge ...
(Date:1/22/2017)... ... , ... Phytocéane invites clients to take an exotic journey deep into the ... MILKY CREAM. Inspired by the beauty of Zanzibar, a Tanzanian archipelago off the coast ... coral to create this gentle, velvety body cream to envelop the skin in moisture ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... InDex Pharmaceuticals Holding AB (publ) today announced ... of the European Crohn,s and Colitis Organisation (ECCO). The ECCO congress ... on inflammatory bowel disease (IBD). The congress is held in ... ... again having been selected to present data at the largest IBD ...
(Date:1/21/2017)... , Jan. 20, 2017 ResMed (NYSE: ... Medical ( Winter Haven, Florida ) today announced they ... parties. BMC and 3B will be permitted to sell their existing ... make a one-time settlement payment to 3B to close the ... did not include an admission of liability or wrongdoing by any ...
(Date:1/21/2017)... 20, 2017 Research and Markets has announced ... Trends - Technology, Route Of Administration, End User - Forecast to ... ... to grow at a CAGR of around 7.8% over the next ... This industry report analyzes the global markets for Advanced Drug Delivery ...
Breaking Medicine Technology: